Advertisement

Rivals Cipla, Natco gain on Novartis drug patent rejection

Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec.

Advertisement
Srividya Iyer|Dec 21, 2014, 02:06:27 IST

Mumbai: Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec.

[caption id="attachment_680976" align="alignleft" width="380"]Reuters

Analysts say that will be a big win for generic drugmakers. Reuters[/caption]

In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.

Advertisement

Analysts say that will be a big win for generic drugmakers given huge difference in prices of monopoly drugs, and as other emerging countries are also expected to follow he apex court's decision.

Cipla and Natco are already selling generic versions of Glivec in India. Natco was up 6 percent, while Cipla rose 2 percent at 2:25 pm

fwireMore from Fwire

Reuters

Handpicked stories, in your inbox
Global stories. Indian perspective. Zero noise.
No Spam. Unsubscribe Any Time.
First Published:Apr 01, 2013, 14:32:31 IST
Advertisement
Advertisement
Advertisement
Advertisement
Up Next